CQ12-1 (GRADE)

P: Patients in intensive care units
I: Enteral nutrition
C: Parental nutrition
O: Mortality, length of hospital stay, length of mechanical ventilation, infection

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Treatment	Placebo	Relative (95% CI)	Absolute (95% CI)		
Mortality (90 day)												
4	randomised trials	serious	not serious	not serious	not serious	none	1015/2424 (41.9%)	962/2420 (39.8%)	**RR 1.05** (0.95 to 1.17)	**20 more per 1,000** (from 20 fewer to 68 more)	⨁⨁⨁◯ Moderate	CRITICAL
Length of hospital stay												
10	randomised trials	very serious	very serious	serious	serious	none	2767	2748	-	**MD 2.51 day lower** (from 4.78 lower to 0.24 lower)	⨁◯◯◯ Very low	CRITICAL
Length of mechanical ventilation												
4	randomised trials	very serious	very serious	not serious	serious	none	277	286	-	**MD 0.36 day lower** (from 0.93 lower to 0.2 higher)	⨁◯◯◯ Very low	CRITICAL
Sepsis (Blood stream infection)												
9	randomised trials	very serious	not serious	not serious	serious	none	51/1479 (3.5%)	82/1497 (5.5%)	**RR 0.66** (0.41 to 1.07)	**19 fewer per 1,000** (from 32 fewer to 4 more)	⨁◯◯◯ Very low	CRITICAL
Pneumonia (Ventilator associated pneumonia)												
8	randomised trials	serious	not serious	not serious	serious	none	150/1520 (9.9%)	181/1546 (11.7%)	**RR 0.85** (0.65 to 1.10)	**18 fewer per 1,000** (from 41 fewer to 12 more)	⨁⨁◯◯ Low	CRITICAL
Abdominal infection (Abdominal abscess, necrotizing pancreatitis)												
7	randomised trials	serious	not serious	not serious	not serious	none	48/1612 (3.0%)	100/1547 (6.5%)	**RR 0.39** (0.29 to 0.53)	**39 fewer per 1,000** (from 46 fewer to 30 fewer)	⨁⨁⨁◯ Moderate	CRITICAL

	JUDGEMENT						
PROBLEM	No	Probably no	**Probably yes**	Yes		Varies	Don't know
DESIRABLE EFFECTS	Trivial	Small	**Moderate**	Large		Varies	Don't know
UNDESIRABLE EFFECTS	Large	Moderate	Small	**Trivial**		Varies	Don't know
CERTAINTY OF EVIDENCE	**Very low**	Low	Moderate	High			No included studies
VALUES	Important uncertainty or variability	Possibly important uncertainty or variability	**Probably no important uncertainty or variability**	No important uncertainty or variability			
BALANCE OF EFFECTS	Favors the comparison	Probably favors the comparison	Does not favor either the intervention or the comparison	**Probably favors the intervention**	Favors the intervention	Varies	Don't know
ACCEPTABILITY	No	Probably no	**Probably yes**	Yes		Varies	Don't know
FEASIBILITY	No	Probably no	Probably yes	**Yes**		Varies	Don't know

CQ12-2 (GRADE)

P: Critically ill patients who received catecholamine/ Hypotensive patients in intensive care units
I: Enteral nutrition
C: Parental nutrition
O: Mortality, length of hospital stay, serious adverse event, infection, serious intestinal complication

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Treatment	Placebo	Relative (95% CI)	Absolute (95% CI)		
Length of hospital stay												
1	randomised trials	serious	not serious	not serious	not serious	none	1202	1208	-	**MD 1 day lower** (from 2.42 lower to 0.42 higher)	⨁⨁⨁◯ Moderate	CRITICAL
Mortality (90 day)												
1	randomised trials	not serious	not serious	not serious	not serious	none	530/1202 (44.1%)	507/1208 (42.0%)	**RR 1.05** (0.96 to 1.15)	**21 more per 1,000** (from 17 fewer to 63 more)	⨁⨁⨁⨁ High	CRITICAL
Intestinal pseudo-obstruction												
1	randomised trials	serious	not serious	not serious	serious	none	11/1202 (0.9%)	3/1208 (0.2%)	**RR 3.69** (1.03 to 12.93)	**7 more per 1,000** (from 0 fewer to 30 more)	⨁⨁◯◯ Low	CRITICAL
Intensive care unit acquired infection)												
1	randomised trials	serious	not serious	not serious	serious	none	173/1202 (14.4%)	194/1208 (16.1%)	**RR 0.90** (0.74 to 1.08)	**16 fewer per 1,000** (from 42 fewer to 13 more)	⨁⨁◯◯ Low	CRITICAL
Intestinal ischemia												
1	randomised trials	serious	not serious	not serious	very serious	none	19/1202 (1.6%)	5/1208 (0.4%)	**RR 3.82** (1.43 to 10.19)	**12 more per 1,000** (from 2 more to 38 more)	⨁◯◯◯ Very low	CRITICAL
Vomit												
1	randomised trials	serious	not serious	not serious	not serious	none	406/1202 (33.8%)	246/1208 (20.4%)	**RR 1.66** (1.46 to 1.87)	**134 more per 1,000** (from 94 more to 177 more)	⨁⨁⨁◯ Moderate	IMPORTANT
Diarrhea												
1	randomised trials	serious	not serious	not serious	not serious	none	432/1202 (35.9%)	393/1208 (32.5%)	**RR 1.10** (0.99 to 1.23)	**33 more per 1,000** (from 3 fewer to 75 more)	⨁⨁⨁◯ Moderate	IMPORTANT

	JUDGEMENT						
PROBLEM	No	Probably no	**Probably yes**	Yes		Varies	Don't know
DESIRABLE EFFECTS	**Trivial**	Small	Moderate	Large		Varies	Don't know
UNDESIRABLE EFFECTS	Large	Moderate	**Small**	Trivial		Varies	Don't know
CERTAINTY OF EVIDENCE	**Very low**	Low	Moderate	High			No included studies
VALUES	Important uncertainty or variability	Possibly important uncertainty or variability	**Probably no important uncertainty or variability**	No important uncertainty or variability			
BALANCE OF EFFECTS	Favors the comparison	**Probably favors the comparison**	Does not favor either the intervention or the comparison	Probably favors the intervention	Favors the intervention	Varies	Don't know
ACCEPTABILITY	No	Probably no	**Probably yes**	Yes		Varies	Don't know
FEASIBILITY	No	Probably no	Probably yes	**Yes**		Varies	Don't know

CQ12-3 (GRADE)

P: Critically ill patients in intensive care units
I: Early enteral nutrition (within 24-48 hours)
C: Late enteral nutrition
O: Mortality, length of hospital stay, serious adverse event, infection

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Treatment	Placebo	Relative (95% CI)	Absolute (95% CI)		
Mortality												
13	randomised trials	serious	not serious	not serious	serious	Publication bias was suspected	34/350 (9.7%)	47/359 (13.1%)	**RR 0.79** (0.52 to 1.19)	**27 fewer per 1,000** (from 63 fewer to 25 more)	⨁◯◯◯ Very low	CRITICAL
Mortality (ICU)												
2	randomised trials	serious	not serious	not serious	serious	none	4/41 (9.8%)	5/39 (12.8%)	**RR 0.81** (0.27 to 2.39)	**24 fewer per 1,000** (from 94 fewer to 178 more)	⨁◯◯◯ Very low	CRITICAL
Mortality (Hospital)												
2	randomised trials	serious	not serious	not serious	very serious	none	2/47 (4.3%)	1/48 (2.1%)	**RR 2.00** (0.19 to 20.90)	**21 more per 1,000** (from 17 fewer to 415 more)	⨁◯◯◯ Very low	CRITICAL
Length of ICU stay												
6	randomised trials	serious	serious	not serious	serious	none	118	115	-	**MD 0.38 day higher** (from 3.89 lower to 4.65 higher)	⨁◯◯◯ Very low	CRITICAL
Length of hospital stay												
5	randomised trials	serious	serious	not serious	serious	none	107	110	-	**MD 0.41 day higher** (from 2.71 lower to 3.53 higher)	⨁◯◯◯ Very low	CRITICAL
Pneumonia												
6	randomised trials	serious	not serious	not serious	serious	none	60/216 (27.8%)	83/225 (36.9%)	**RR 0.77** (0.53 to 1.11)	**85 fewer per 1,000** (from 173 fewer to 41 more)	⨁◯◯◯ Very low	CRITICAL
Bacteremia												
6	randomised trials	serious	not serious	not serious	serious	none	59/205 (28.8%)	38/149 (25.5%)	**RR 1.19** (0.73 to 1.94)	**48 more per 1,000** (from 69 fewer to 240 more)	⨁◯◯◯ Very low	CRITICAL

	JUDGEMENT						
PROBLEM	No	Probably no	**Probably yes**	Yes		Varies	Don't know
DESIRABLE EFFECTS	Trivial	Small	**Moderate**	Large		Varies	Don't know
UNDESIRABLE EFFECTS	Large	Moderate	**Small**	Trivial		Varies	Don't know
CERTAINTY OF EVIDENCE	**Very low**	Low	Moderate	High			No included studies
VALUES	Important uncertainty or variability	Possibly important uncertainty or variability	**Probably no important uncertainty or variability**	No important uncertainty or variability			
BALANCE OF EFFECTS	Favors the comparison	Probably favors the comparison	Does not favor either the intervention or the comparison	**Probably favors the intervention**	Favors the intervention	Varies	Don't know
ACCEPTABILITY	No	Probably no	**Probably yes**	Yes		Varies	Don't know
FEASIBILITY	No	Probably no	Probably yes	**Yes**		Varies	Don't know

CQ12-4 (GRADE)

P: Critically ill patients in intensive care units
I: Patients receive enteral nutrition less than their energy expenditure
C: Patients receive enteral nutrition as same as their energy expenditure
O: Mortality, length of hospital stay, serious adverse event, infection

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Treatment	Placebo	Relative (95% CI)	Absolute (95% CI)		
Mortality												
18	randomised trials	not serious	not serious	not serious	not serious	none	1277/6317 (20.2%)	1297/6262 (20.7%)	**RR 0.99** (0.89 to 1.10)	**2 fewer per 1,000** (from 23 fewer to 21 more)	⨁⨁⨁◯ Moderate	CRITICAL
Mortality (Hospital)												
10	randomised trials	not serious	serious	not serious	not serious	none	949/5312 (17.9%)	978/5269 (18.6%)	**RR 0.96** (0.83 to 1.12)	**7 fewer per 1,000** (from 32 fewer to 22 more)	⨁⨁◯◯ Low	CRITICAL
Length of hospital stay												
10	randomised trials	not serious	serious	not serious	not serious	none	3371	3357	-	**MD 0.35 day lower** (from 2.68 lower to 1.99 higher)	⨁⨁◯◯ Low	CRITICAL
Infection												
11	randomised trials	not serious	serious	not serious	not serious	none	751/3144 (23.9%)	810/3101 (26.1%)	**RR 0.99** (0.83 to 1.18)	**3 fewer per 1,000** (from 44 fewer to 47 more)	⨁⨁◯◯ Low	CRITICAL
Pneumonia												
10	randomised trials	not serious	not serious	not serious	serious	none	600/3935 (15.2%)	686/3843 (17.9%)	**RR 0.86** (0.72 to 1.02)	**25 fewer per 1,000** (from 50 fewer to 4 more)	⨁⨁⨁◯ Moderate	CRITICAL
Bacteremia												
9	randomised trials	not serious	not serious	not serious	not serious	none	460/5416 (8.5%)	491/5352 (9.2%)	**RR 0.94** (0.80 to 1.12)	**6 fewer per 1,000** (from 18 fewer to 11 more)	⨁⨁⨁◯ Moderate	CRITICAL
Catheter related blood stream infection												
5	randomised trials	not serious	not serious	not serious	very serious	Publication bias was suspected	19/816 (2.3%)	36/792 (4.5%)	**RR 0.59** (0.26 to 1.33)	**19 fewer per 1,000** (from 34 fewer to 15 more)	⨁⨁◯◯ Low	CRITICAL

	JUDGEMENT						
PROBLEM	No	Probably no	**Probably yes**	Yes		Varies	Don't know
DESIRABLE EFFECTS	Trivial	**Small**	Moderate	Large		Varies	Don't know
UNDESIRABLE EFFECTS	Large	Moderate	Small	Trivial		Varies	**Don't know**
CERTAINTY OF EVIDENCE	Very low	Low	**Moderate**	High			No included studies
VALUES	Important uncertainty or variability	Possibly important uncertainty or variability	**Probably no important uncertainty or variability**	No important uncertainty or variability			
BALANCE OF EFFECTS	Favors the comparison	Probably favors the comparison	Does not favor either the intervention or the comparison	**Probably favors the intervention**	Favors the intervention	Varies	Don't know
ACCEPTABILITY	No	Probably no	**Probably yes**	Yes		Varies	Don't know
FEASIBILITY	No	Probably no	Probably yes	**Yes**		Varies	Don't know

CQ12-5 (GRADE)

P: Critically ill patients in intensive care units
I: Use of supplemental parental nutrition
C: Not use of supplemental parental nutrition
O: Mortality, infection

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Treatment	Placebo	Relative (95% CI)	Absolute (95% CI)		
Mortality (90 day)												
1	randomised trials	not serious	not serious	not serious	very serious	none	17/60 (28.3%)	18/60 (30.0%)	**RR 0.94** (0.54 to 1.65)	**18 fewer per 1,000** (from 138 fewer to 195 more)	⨁⨁◯◯ Low	CRITICAL
Blood stream infection												
3	randomised trials	serious	serious	not serious	very serious	none	19/241 (7.9%)	22/263 (8.4%)	**RR 1.07** (0.26 to 4.50)	**6 more per 1,000** (from 62 fewer to 293 more)	⨁◯◯◯ Very low	CRITICAL
Respiratory infection												
4	randomised trials	serious	not serious	not serious	serious	none	70/301 (23.3%)	98/323 (30.3%)	**RR 0.79** (0.53 to 1.16)	**64 fewer per 1,000** (from 143 fewer to 49 more)	⨁⨁◯◯ Low	CRITICAL
Urinary tract infection												
3	randomised trials	serious	not serious	not serious	very serious	none	24/265 (9.1%)	23/285 (8.1%)	**RR 1.31** (0.50 to 3.46)	**25 more per 1,000** (from 40 fewer to 199 more)	⨁◯◯◯ Very low	CRITICAL
Abdominal infection												
2	randomised trials	serious	not serious	not serious	very serious	none	12/205 (5.9%)	8/225 (3.6%)	**RR 2.47** (0.21 to 29.33)	**52 more per 1,000** (from 28 fewer to 1000 more)	⨁◯◯◯ Very low	CRITICAL

	JUDGEMENT						
PROBLEM	No	Probably no	**Probably yes**	Yes		Varies	Don't know
DESIRABLE EFFECTS	Trivial	Small	**Moderate**	Large		Varies	Don't know
UNDESIRABLE EFFECTS	Large	**Moderate**	Small	Trivial		Varies	Don't know
CERTAINTY OF EVIDENCE	**Very low**	Low	Moderate	High			No included studies
VALUES	Important uncertainty or variability	Possibly important uncertainty or variability	**Probably no important uncertainty or variability**	No important uncertainty or variability			
BALANCE OF EFFECTS	Favors the comparison	Probably favors the comparison	Does not favor either the intervention or the comparison	**Probably favors the intervention**	Favors the intervention	Varies	Don't know
ACCEPTABILITY	No	Probably no	**Probably yes**	Yes		Varies	Don't know
FEASIBILITY	No	Probably no	**Probably yes**	Yes		Varies	Don't know

CQ12-6 (GRADE)

P: Critically ill patients in intensive care units
I: Patients receive more than 1 g/kg/day of protein
C: Patients receive less than 1 g/kg/day of protein
O: Mortality, length of hospital stay, length of mechanical ventilation, duration of antimicrobial agents, ADL score, physical function, muscle volume

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Treatment	Placebo	Relative (95% CI)	Absolute (95% CI)		
Mortality												
5	randomised trials	not serious	not serious	serious	serious	none	65/366 (17.8%)	66/364 (18.1%)	**RR 0.98** (0.72 to 1.34)	**4 fewer per 1,000** (from 51 fewer to 62 more)	⨁⨁◯◯ Low	CRITICAL
Length of hospital stay												
5	randomised trials	serious	not serious	serious	not serious	none	369	364	-	**MD 2.36 day higher** (from 1.42 lower to 6.15 higher)	⨁⨁◯◯ Low	CRITICAL
Length of mechanical ventilation												
5	randomised trials	serious	not serious	serious	not serious	none	390	387	-	**MD 0.07 day higher** (from 0.02 lower to 0.16 higher)	⨁⨁◯◯ Low	CRITICAL
Duration of antimicrobial agent												
1	randomised trials	serious	not serious	serious	not serious	none	239	235	-	**MD 0.15 day higher** (from 0.07 higher to 0.23 higher)	⨁⨁◯◯ Low	CRITICAL
Physical function												
3	randomised trials	serious	not serious	serious	serious	none	250	239	-	**MD 0.45 higher** (from 4.57 lower to 5.46 higher)	⨁◯◯◯ Very low	CRITICAL
Muscle volume												
2	randomised trials	serious	not serious	serious	serious	none	77	80	-	**MD 0.2 higher** (from 0.56 lower to 0.96 higher)	⨁◯◯◯ Very low	CRITICAL

	JUDGEMENT						
PROBLEM	No	Probably no	**Probably yes**	Yes		Varies	Don't know
DESIRABLE EFFECTS	**Trivial**	Small	Moderate	Large		Varies	Don't know
UNDESIRABLE EFFECTS	Large	Moderate	**Small**	Trivial		Varies	Don't know
CERTAINTY OF EVIDENCE	**Very low**	Low	Moderate	High			No included studies
VALUES	Important uncertainty or variability	Possibly important uncertainty or variability	**Probably no important uncertainty or variability**	No important uncertainty or variability			
BALANCE OF EFFECTS	Favors the comparison	**Probably favors the comparison**	Does not favor either the intervention or the comparison	Probably favors the intervention	Favors the intervention	Varies	Don't know
ACCEPTABILITY	No	Probably no	**Probably yes**	Yes		Varies	Don't know
FEASIBILITY	No	Probably no	**Probably yes**	Yes		Varies	Don't know

CQ12-7-1 (GRADE)

P: Critically ill patients in intensive care units
I: Use of vitamin C
C: Placebo or not use of vitamin C
O: Mortality, length of hospital stay, acute kidney injury

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Treatment	Placebo	Relative (95% CI)	Absolute (95% CI)		
Mortality (28 day)												
5	randomised trials	not serious	serious	not serious	serious	none	248/837 (29.6%)	246/809 (30.4%)	**RR 0.82** (0.57 to 1.17)	**55 fewer per 1,000** (from 131 fewer to 52 more)	⨁⨁◯◯ Low	CRITICAL
Mortality (Hosiptal)												
7	randomised trials	serious	serious	not serious	serious	none	321/923 (36.2%)	317/875 (36.2%)	**RR 0.93** (0.71 to 1.23)	**25 fewer per 1,000** (from 105 fewer to 83 more)	⨁◯◯◯ Very low	CRITICAL
Length of ICU stay												
6	randomised trials	serious	not serious	not serious	not serious	none	717	677	-	**MD 0.58 day lower** (from 1.45 lower to 0.28 higher)	⨁⨁⨁◯ Moderate	CRITICAL
Length of hospital stay												
5	randomised trials	serious	not serious	not serious	not serious	none	802	754	-	**MD 0.64 day higher** (from 1.24 lower to 2.52 higher)	⨁⨁⨁◯ Moderate	CRITICAL
Acute kidney injury												
2	randomised trials	serious	not serious	not serious	serious	none	75/126 (59.5%)	75/122 (61.5%)	**RR 0.97** (0.82 to 1.15)	**18 fewer per 1,000** (from 111 fewer to 92 more)	⨁⨁◯◯ Low	CRITICAL

	JUDGEMENT						
PROBLEM	No	Probably no	**Probably yes**	Yes		Varies	Don't know
DESIRABLE EFFECTS	Trivial	**Small**	Moderate	Large		Varies	Don't know
UNDESIRABLE EFFECTS	Large	Moderate	Small	**Trivial**		Varies	Don't know
CERTAINTY OF EVIDENCE	**Very low**	Low	Moderate	High			No included studies
VALUES	Important uncertainty or variability	Possibly important uncertainty or variability	**Probably no important uncertainty or variability**	No important uncertainty or variability			
BALANCE OF EFFECTS	Favors the comparison	Probably favors the comparison	Does not favor either the intervention or the comparison	**Probably favors the intervention**	Favors the intervention	Varies	Don't know
ACCEPTABILITY	No	Probably no	**Probably yes**	Yes		Varies	Don't know
FEASIBILITY	No	Probably no	**Probably yes**	Yes		Varies	Don't know

CQ12-7-2 (GRADE)

P: Critically ill patients in intensive care units
I: Use of vitamin D
C: Placebo or not use of vitamin D
O: Mortality, length of hospital stay, hypercalcemia

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Treatment	Placebo	Relative (95% CI)	Absolute (95% CI)		
Mortality (28 or 30 day)												
6	randomised trials	not serious	not serious	serious	serious	none	166/991 (16.8%)	161/975 (16.5%)	**RR 0.95** (0.70 to 1.28)	**8 fewer per 1,000** (from 50 fewer to 46 more)	⨁⨁◯◯ Low	CRITICAL
Mortality (90 day)												
3	randomised trials	not serious	not serious	very serious	serious	none	132/584 (22.6%)	113/573 (19.7%)	**RR 1.14** (0.91 to 1.43)	**28 more per 1,000** (from 18 fewer to 85 more)	⨁◯◯◯ Very low	CRITICAL
Mortality (Hospital)												
4	randomised trials	serious	not serious	serious	serious	none	78/317 (24.6%)	107/315 (34.0%)	**RR 0.72** (0.47 to 1.12)	**95 fewer per 1,000** (from 180 fewer to 41 more)	⨁◯◯◯ Very low	CRITICAL
Length of ICU stay												
6	randomised trials	not serious	serious	serious	not serious	none	358	337	-	**MD 0.24 day lower** (from 3.72 lower to 3.23 higher)	⨁⨁◯◯ Low	CRITICAL
Length of hospital stay												
9	randomised trials	serious	very serious	serious	not serious	none	948	938	-	**MD 0.32 day lower** (from 2.15 lower to 1.5 higher)	⨁◯◯◯ Very low	CRITICAL
Hypercalcemia												
5	randomised trials	not serious	serious	serious	very serious	none	15/637 (59.5%)	15/639 (2.3%)	**RR 0.70** (0.13 to 3.77)	**7 fewer per 1,000** (from 20 fewer to 65 more)	⨁◯◯◯ Very low	CRITICAL

	JUDGEMENT						
PROBLEM	No	Probably no	**Probably yes**	Yes		Varies	Don't know
DESIRABLE EFFECTS	**Trivial**	Small	Moderate	Large		Varies	Don't know
UNDESIRABLE EFFECTS	Large	Moderate	Small	**Trivial**		Varies	Don't know
CERTAINTY OF EVIDENCE	**Very low**	Low	Moderate	High			No included studies
VALUES	Important uncertainty or variability	Possibly important uncertainty or variability	**Probably no important uncertainty or variability**	No important uncertainty or variability			
BALANCE OF EFFECTS	Favors the comparison	Probably favors the comparison	**Does not favor either the intervention or the comparison**	Probably favors the intervention	Favors the intervention	Varies	Don't know
ACCEPTABILITY	No	Probably no	Probably yes	Yes		**Varies**	Don't know
FEASIBILITY	No	**Probably no**	Probably yes	Yes		Varies	Don't know